Abnormal choline phospholipid metabolism in breast and ovary cancer: Molecular bases noninvasive imaging approaches

Current Medical Imaging Reviews

Volumn 3, Issue 2, 2007, Pages 123-137

  Podo, Franca ^a   Sardanelli, Francisco ^b   Iorio, Egidio ^a   Canese, Rosella ^a   Carpinelli, Giulia ^a   Fausto, Alfonso ^b   Canevari, Silvana ^c  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

1H MRS; Breast cancer; Choline metabolism; Ovary cancer; PET; Phosphatidylcholine cycle

Indexed keywords

CARBON 11; CHOLINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

BREAST CANCER; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; FEMALE; FOLLOW UP; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVARY CANCER; PHENOTYPIC VARIATION; PHOSPHOLIPID BLOOD LEVEL; PHOSPHOLIPID METABOLISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY AND SPECIFICITY; SPECTRAL SENSITIVITY; TUMOR GROWTH;

EID: 34248681296     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340507780619160     Document Type: Review

References (118)

1. Negendank WG. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303-24.
2. 31P MRS of experimental tumours. NMR Biomed 1993; 6: 345-65.
3. Podo F. Tumour phospholipid metabolism. Review article. NMR Biomed 1999; 12: 413-39.
4. Ackerstaff E, Glunde K, Bhujwalla ZW. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 90: 525-33.
5. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006; 3: 496-506.
6. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-4.
7. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62:1966-70.
8. Tse GM, Yeung DK, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 2006 Oct 19 [Epub ahead of print].
9. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61: 3599-603.
10. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006; 24: 825-32.
11. Mori N, Delsite R, Natarajan K, Kulawiec M, Bhujwalla ZM, Singh KK. Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging 2004; 3: 319-23.
12. 1H MR spectroscopy: initial results. Radiology 2004; 232: 599-605.
13. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology 2006; 3: 958-69.
14. Ferretti A, D'Ascenzo S, Knijn A, Iorio E, Dolo V, Podo F. Detection of polyol accumulation in a new ovarian carcinoma cell line, CABA 1: a 1H NMR study. Br J Cancer 2002; 86: 1180-87.
15. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res 2005; 65: 9369-76.
16. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycles. Trends Biochem Sci 1989; 14: 28-30.
17. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identifiedin cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7: 1109-23.
18. http://www.imaginis.com/breasthealth/statistics.asp
19. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
20. Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF. Molecular classification of breast cancer: limitations and potential. Oncologist 2006; 11: 868-77.
21. Kuhl CK, Kuhn W, Schild H. Management of women at high risk for breast cancer: new imaging beyond mammography. Breast 2005; 14: 480-6.
22. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
23. Sardanelli F, Podo F. D'Agnolo G, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk of breast cancer: Interim results. Radiology, (published online before print January 23, 2007).
24. Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 2006 Sep 29 [Epub ahead of print]
25. Koutcher JA, Goldsmith M, Damadian R. NMR in cancer. X. A malignancy index to discriminate normal and cancerous tissue. Cancer 1978; 41: 174-82.
26. Heywang SH. Status of research in the field of diagnostic imaging of the breast with particular reference to magnetic resonance tomography. Röntgenpraxis 1988; 41: 384-94.
27. Heywang SH, Hahn D, Schmidt H, et al. MRI of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10: 199-204.
28. Vomweg TW, Buscema M, Kauczor HU, et al. Improved artificial neural networks in prediction of malignancy of lesions in contrast-enhanced MR-mammography. Med Phys 2003; 30: 2350-9.
29. Kuhl CK, Schild HH, Morakkabati N. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 2005; 236: 789-800.
30. 31P magnetic resonance (MR) spectroscopy. Breast 1994; 3: 20-3.
31. 31P MR spectroscopy of benign and malignant breast tumors. Korean J Radiol 2001; 2: 80-6.
32. Mountford CE, Doran S, Lean CL, Russell P. Proton MRS can determine the pathology of human cancers with a high level of accuracy. Chem Rev 2004; 104: 3677-704.
33. Pathak AP, Gimi B, Glunde K, Ackerstaff E, Artemov D, Bhujwalla ZM. Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol. 2004; 386: 3-60.
34. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005; 7:287-326.
35. Tosi R and Tugnoli V Eds, Nuclear Magnetic Resonance Spectroscopy in the study of neoplastic tissue. New York, Nova Science Publisher, Inc. 2005.
36. 18F-dihydroxyphenylalanine, 18F-choline and 18F-fluoride in bone imaging with emphasis on prostate and breast. Sem Nucl Med 2006; 36: 73-92.
37. Parkin DM, Whelan SL, Falay J, Teppo L, Thomas DB. Cancer incidence in five continents. VIII. Lyon (France): IARC Press; 2002.
38. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
39. Bell DA. Origins and molecular pathology of ovarian cancer. Mod.Pathol 2005; 18 Suppl 2:S19-S32.
40. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 19-37.
41. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164: 1511-8.
42. Classe JM, Fontanelli R, Bischof-Delaloye A, Chatal JF. Ovarian cancer management. Practice guidelines for nuclear physicians. Q J Nucl Med Mol Imaging 2004; 48: 143-9.
43. Coakley FV. Staging ovarian cancer: role of imaging. Radiol Clin North Am 2002; 40: 609-36.
44. Imaoka I, Wada A, Kaji Y, et al. Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics 2006; 26: 1431-48.
45. Low RN, Duggan B, Barone RM, Saleh F, and Song SYT. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology 2005; 235: 918-26.
46. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am 2001; 39: 883-917.
47. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histological findings. Radiology 2004; 433-40.
48. Nanni C, Rubello D, Farsad M, et al. (18)F_FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31: 792-7.
49. Reinhardt MJ, Matthiews A, Biersack HJ. PET-imaging in tumors of the reproductive tract. Q J Nucl Med 2002; 46: 105-12.
50. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996; 20: 4630-5.
51. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999; 19: 1737-46.
52. Vance JE and Vance DE. Phospholipid biosynthesis in mammalian cells. Biochem Cell Biol 2004; 82: 113-28.
53. Warden CH, Friedkin M. Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochim Biophys Acta 1984; 792: 270-80.
54. Macara IG. Elevated phosphocholine concentration in ras-transformed NIH 3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown Mol Cell Biol 1989; 9: 325-8.
55. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002; 296: 580-3.
56. Ramirez de Molina A, Gutierrez R, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21: 4317-22.
57. Al-Saffar NM, Troy H, Ramirez de Molina A, et al. Non invasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res 2006; 66: 427-34.
58. Ramirez de Molina AR, Banez-Coronel M, Gutierrez R, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res 2004; 64: 6732-9.
59. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 2005; 65: 11034-43.
60. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Progr Lipid Res 2004; 43: 266-81.
61. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001; 4: 419-26.
62. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004; 31: 859-65.
63. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42: 1805-14.
64. 18F-Fluorocholine: a new oncologic PET tracer. J Nucl Med 2001; 42: 1915-17.
65. 1H NMR studies. Israel J Chem 1992; 32: 47-54.
66. 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998; 8: 1191-7.
67. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209: 269-75.
68. 1H MR spectroscopy. J Magn Reson Imaging 1999; 10: 159-64.
69. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy - Initial results. Radiology 2001; 220: 40-6.
70. Jagannathan NR, Kumar M, Seenu V, et al. GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001; 84:1016-22.
71. Bakken IJ, Gribbestad IS. External standard method for the in vivo quantification of choline-compounds in breast tumors by proton MR spectroscopy at 1.5 T. proton MR spectroscopy at 1.5 Tesla. Magn Reson Med 2001; 46: 189-92.
72. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 200 1; 68: 45-54.
73. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002; 94: 1197-203.
74. Tse GM, Cheung HS, Pang LM, et al. Characterization of breast with proton MR spectroscopy: comoparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 2003; 181: 1267-72.
75. 1H-MRS evaluation of malignant and benign breast diseases. Breast 2003; 12: 179-82.
76. 1H MR spectroscopy. Magn Reson Imaging 2003; 50: 1134-43.
77. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004; 232: 585-91.
78. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Blumke DB. Proton MR spectroscopic imaging of human breast cancer: A preliminary study. J Magn Reson Imaging 2004; 19:68-75.
79. 1H MRS at 1.5 T. Eur Radiol 2005; 15:1037-43.
80. Meisamy S, Bolan PJ, Baker EH, et al. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology 2005; 236:465-75.
81. Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwalla ZM, Bluemke DA. Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging. 2005; 21:23-8.
82. Bartella L, Morris EA, Dershaw DD, et al. Proton spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: Preliminary study. Radiology 2006; 239: .686-92.
83. Yeung DK, Yang WT, Tse GM. Breast cancer. in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 2002; 225:190-7.
84. 1H magnetic resonance spectroscopy: a pilot study. Magn Reson Imaging 2004; 22: 697-706.
85. Seenu V, Pavan Kumar MNP, Sharma U, Gupta SD, Mehta SN, Jagannathan NR. Potential of magnetic resonance spectroscopy to detect metastasis in axillary lymph nodes in breast cancer. Magn Reson Imaging 2005; 23:1005-10.
86. Salibi N, Brown MA. Clinical MR spectroscopy. First principles. New York: Wiley-Liss, 1998: 75-80.
87. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 1994; 7: 181-194.
88. MacKinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997; 204: 661-6.
89. Cheng LL, Chang IW, Smith BL, Gonzales RG. Evaluation of human breast ductal carcinoma with higli-resolution magic-angle spirming proton magnetic resonance spectroscopy. J Magn Reson 1998; 135: 194-202.
90. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Chibbestad IS. High-resolution magic angle spinning HR MAS of breast cancer tissue. NMR Biomed 2002; 15: 327-37.
91. 1H NMR in solid phase organic synthesis. J Org Chem 1994; 59: 7955-56.
92. Bathen TF, Jensen M Sitter B, et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 2006; Oct 24 [Epub ahead of print].
93. American College of Radiology. Reporting system. In: Breast Imaging Reporting and data System (BI-RADS). 3rd ed. Reston, VA: American College of Radiology, 1998.
94. 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminate analysis. Magn Reson Med 1997; 38: 569-76.
95. H NMR of tissue biopsies. Biochem. Cell Biol 1998; 76: 472-476.
96. Boss EA, Moolenaar SH, Massuger LF, et al. High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed 2000; 13: 297-305.
97. Okada T, Harada K Matsuzaki K, Nishitani H, Aono T. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging 2001; 13: 912-7.
98. Hascalik S, Celik O, Sarac K, Meydanli MM, Alkan A, Mizrak B. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest. 2005; 60: 121-7.
99. 31P NMR spectroscopy measurements of human ovarian carcinoma xenografts: relationships to tumor volume, growth rate, necrotic fraction and differentiation status. Radiother Oncol 1988; 12: 315-26.
100. Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response. Int J Gynecol Cancer 2006; 16 Suppl 1:111-7.
101. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006; 66: 8633-9.
102. Kim KS, Sengupta S, Berk M, et al. Hypoxia Enhances Lysophosphatidic Acid Responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 2006; 66: 7983-90.
103. Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 2005; 5: 1079-94.
104. Kumar R, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 2. Expert Rev Anticancer Ther 2006;6: 625-40.
105. Mankoff DA, Eubank WB. Current and future use of positron emission tomography (PET) in breast cancer. J Mammary Gland Biol Neoplasia 2006; 11: 125-136.
106. Jager PL, de Korte MA, Lub-de Hooge MN, et al. Molecular imaging: what can be used today. Cancer Imaging 2005; 5 Spec No A: S27-32.
107. Kumar R, Chauhan A, Jana S, Dadparvar S. Positron emission tomography in gynecological malignancies. Expert Rev Anticancer Ther 2006; 6:1033-44.
108. Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005; 23: 1664-73.
109. Messa C, Di Muzio N, Picchio M, Gilardi MC, Bettinardi V, Fazio F. PET/ CT and radiotherapy. Q J Nucl Mod Mol Imaging 2006; 50: 4-14.
110. Guller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?. J Natl Cancer Inst 2003; 95: 1040-3.
111. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90: 105-12.
112. 18F-FLT)-a pilot study. Eur J Surg Oncol 2006; 32: 39-43.
113. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006; 24: 2793-9.
114. 18F]FDG). Gynecol Oncol 1993; 51: 197-204.
115. Lapela, M, Leskinen-Kallio S, Varpula M, et al. Metabolic imaging of ovarian tumors with carbon-11 -methionine: a PET study. J Nucl Med 1995; 36: 2196-200.
116. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005; 97: 183-91.
117. Reinhardt MJ, Matthies A, Biersack HJ. PET-imaging in tumors of the reproductive tract. Q J Nucl Med 2002; 46: 105-12.
118. 18F-FDG PET. J Nucl Med 2003; 44: 1051-6.